Australian Trade Mark Search

Australian Trade Mark Search is the Australian Government’s trade mark search system.

Additional fields:

Trade mark 2617433

IR number 1895694
Words BLUEFIN
Image
Image description
Status protected: Registered/protected
Priority date 04 Jun 2025 (Convention)
Classes 5, 42
Kind Word
Dates
Renewal due 03 Dec 2035
Registration advertised / published 17 Apr 2026
Entered on Register 17 Apr 2026
Acceptance advertised / published 10 Feb 2026
Acceptance 10 Feb 2026
IR notification 08 Jan 2026
Filing 03 Dec 2025
Registered from 03 Dec 2025

Owner Address for service
Bluefin Biomedicine, Inc.

IR Contact

Keith Toms, Esq. McCarter & English, LLP


Goods & Services
Class 5: Antibodies for medical purposes; diagnostic biomarker reagents for medical purposes; protein arrays for medical diagnosis purposes; diagnostic kits consisting primarily of monoclonal antibodies, buffers, and reagents for use in disease testing; diagnostic preparations for medical purposes; pharmaceutical preparations for the treatment of cancer, oncologic diseases and disorders, inflammation and immunity diseases and disorders, immunodeficiency diseases and disorders, genetic diseases and disorders, metabolic diseases and disorders, neurodegenerative diseases and disorders, kidney diseases and disorders, eye diseases and disorders, uveitis, glomerulosclerosis, glomerulonephritis, cardiovascular diseases and disorders.
Class 42: Pharmaceutical research and development; research and development services in the field of antibodies; providing medical and scientific research information; consulting services in the field of pharmaceutical research and development; consulting services in the field of biotechnology; consulting services in the field of pharmacogenetics; research and development in the field of biologics, namely, antibodies and peptides for the field of cancer, immunology and inflammation diseases, autoimmune diseases, autoimmune disorders, genetic disorders, metabolic diseases, neurodegenerative diseases, kidney diseases, eye diseases, uveitis, glomerulosclerosis, glomerulonephritis, and cardiovascular diseases; research and development in the field of pharmaceuticals, biopharmaceuticals, and biotechnologies for the treatment of cancer, immunology and inflammation diseases, autoimmune diseases, autoimmune disorders, genetic disorders, metabolic diseases, neurodegenerative diseases, kidney diseases, eye diseases, uveitis, glomerulosclerosis, glomerulonephritis, and cardiovascular diseases; research and development in the field of biotechnology, pharmaceutical research and development, laboratory testing, diagnostics, and pharmacogenetics in the field of cancer, immunology and inflammation diseases, autoimmune diseases, autoimmune disorders, genetic disorders, metabolic diseases, neurodegenerative diseases, kidney diseases, eye diseases, uveitis, glomerulosclerosis, glomerulonephritis, and cardiovascular diseases; research and development in the field of proteomics, transcriptomics, and bioinformatics.

Convention details
Date 04 Jun 2025
Number 99218525
Country UNITED STATES OF AMERICA

Indexing constituents
Word Image